Division of Gilead Sciences Inc.
Latest From Pharmasset Inc.
Expensive acquisitions are in the spotlight during earnings season. The purchases of Kite and Celgene by Gilead and Bristol-Myers Squibb are not turning out to be what was written on the tin.
Acquisitions and licensing are core to pharma and big biotech growth as pipelines thin and assets lose patent protection. Looking back at significantly sized acquisitions over just five years reveals that half of 2014’s acquisitions can already be judged as outright failures or, at best, questionable. But some lessons can be learned from dud deals.
At EASL, Gilead indicated it may not take any of its current NASH candidates forward as monotherapy options. Trial collaboration with Novo Nordisk may suggest pessimism toward selonsertib after Phase III disappointment.
The venture capitalist builds biotechs from scratch and with this latest fund, MPM is looking to add to its sector-leading record of 49 FDA-approved drugs and over 100 IPOs and acquisitions.
- Drug Discovery Tools
- Therapeutic Areas
- Infectious & Viral Diseases
- North America
- Parent & Subsidiaries
- Gilead Sciences Inc.
- Senior Management
P. Schaefer Price, CEO
Kurt Leutzinger, CFO
Abel De La Rosa, PhD, SVP, Bus. Dev. & Scientific Affairs
Michael J Otto, PhD, CSO
Patrick T Higgins, EVP, Mktg. & Sales
- Contact Info
Phone: (609) 613-4100
303-A College Rd. E.
Princeton, NJ 08540
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.